Compare ARBEW & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARBEW | TARA |
|---|---|---|
| Founded | 2015 | N/A |
| Country | Israel | United States |
| Employees | 144 | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 165.5M |
| IPO Year | N/A | N/A |
| Metric | ARBEW | TARA |
|---|---|---|
| Price | $0.16 | $5.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $20.33 |
| AVG Volume (30 Days) | 32.4K | ★ 1.3M |
| Earning Date | 03-05-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $768,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.13 | $2.77 |
| 52 Week High | $1.25 | $7.82 |
| Indicator | ARBEW | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 37.16 | 46.31 |
| Support Level | $0.14 | $5.07 |
| Resistance Level | $0.24 | $6.37 |
| Average True Range (ATR) | 0.03 | 0.47 |
| MACD | -0.00 | -0.18 |
| Stochastic Oscillator | 8.74 | 23.64 |
Arbe Robotics Ltd is a provider of 4D Imaging Radar solutions enabling driver-assist systems while paving the way for fully autonomous driving. It is a research and development company in the field of chips for Advanced radar systems, which are mainly intended to be used as Advanced Driver Assistance Systems (ADAS) adapted for autonomous vehicles as well as for non-automotive uses. Its geographical segments include Sweden, China, Germany, Hong Kong, USA, Israel, Switzerland, Italy, and others.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).